Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

(2017) Joshua Bauml et al.   JOURNAL OF CLINICAL ONCOLOGY

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

(2017) Narek Shaverdian et al.   LANCET ONCOLOGY

Radiotherapy and immunotherapy: a beneficial liaison?

(2017) Ralph R. Weichselbaum et al.   Nature Reviews Clinical Oncology

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Barriers to Radiation-Induced In Situ Tumor Vaccination

(2017) Erik Wennerberg et al.   Frontiers in Immunology

Can immunostimulatory agents enhance the abscopal effect of radiotherapy?

(2016) Antonin Levy et al.   EUROPEAN JOURNAL OF CANCER

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

(2016) Laura Q.M. Chow et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents

(2016) Jeffrey S. Weber et al.   ONCOLOGIST

Salvage surgery for neck residue or recurrence of nasopharyngeal carcinoma after primary radiotherapy: options of surgical methods and regions

(2016) Sheng-ye Wang et al.   World Journal of Surgical Oncology

Current clinical trials testing the combination of immunotherapy with radiotherapy

(2016) Josephine Kang et al.   Journal for ImmunoTherapy of Cancer

The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant

(2015) Kobe Reynders et al.   CANCER TREATMENT REVIEWS

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

(2015) M. Freeman-Keller et al.   CLINICAL CANCER RESEARCH

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination of Radiotherapy and Immune Checkpoint Inhibitors

(2015) Karsten A. Pilones et al.   SEMINARS IN RADIATION ONCOLOGY

In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment

(2015) Claire Vanpouille-Box et al.   VACCINE

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

(2015) Martina Sanlorenzo et al.   JAMA Dermatology

Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy

(2015) Jennifer A. Lo et al.   JAMA Oncology

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

(2014) A. B. Sharabi et al.   Cancer Immunology Research

Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody Therapy

(2011) Yulia Bronstein et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Intensity modulated or fractionated stereotactic reirradiation in patients with recurrent nasopharyngeal cancer

(2011) Falk Roeder et al.   Radiation Oncology

Current treatment options for recurrent nasopharyngeal cancer

(2010) Carlos Suárez et al.   EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY

Reirradiation of Locally Recurrent Nasopharynx Cancer With External Beam Radiotherapy With or Without Brachytherapy

(2009) Lawrence Koutcher et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Intensity-Modulated Proton Therapy Versus Helical Tomotherapy in Nasopharynx Cancer: Planning Comparison and NTCP Evaluation

(2008) Lamberto Widesott et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS